-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Large Decrease in Short Interest
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Large Decrease in Short Interest
Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) was the target of a significant drop in short interest in December. As of December 30th, there was short interest totalling 592,200 shares, a drop of 17.4% from the December 15th total of 717,000 shares. Based on an average daily volume of 133,700 shares, the short-interest ratio is presently 4.4 days.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Annandale Capital LLC purchased a new stake in shares of Cue Biopharma in the 3rd quarter worth about $145,000. Sigma Planning Corp grew its position in shares of Cue Biopharma by 12.8% in the 3rd quarter. Sigma Planning Corp now owns 188,424 shares of the company's stock worth $420,000 after buying an additional 21,318 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Cue Biopharma in the 3rd quarter worth about $73,000. Voss Capital LLC grew its position in shares of Cue Biopharma by 100.0% in the 3rd quarter. Voss Capital LLC now owns 200,000 shares of the company's stock worth $446,000 after buying an additional 100,000 shares during the period. Finally, P.A.W. Capital Corp grew its position in shares of Cue Biopharma by 14.3% in the 3rd quarter. P.A.W. Capital Corp now owns 200,000 shares of the company's stock worth $446,000 after buying an additional 25,000 shares during the period. 31.87% of the stock is owned by hedge funds and other institutional investors.
Get Cue Biopharma alerts:Cue Biopharma Price Performance
NASDAQ:CUE traded up $0.11 during mid-day trading on Friday, hitting $3.49. 48,612 shares of the stock traded hands, compared to its average volume of 94,893. The business's 50-day moving average price is $3.16 and its 200 day moving average price is $2.98. Cue Biopharma has a 12-month low of $2.18 and a 12-month high of $11.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.04 and a quick ratio of 6.04.
Cue Biopharma (NASDAQ:CUE – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.07. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.65 million. Cue Biopharma had a negative net margin of 500.66% and a negative return on equity of 77.78%. Research analysts predict that Cue Biopharma will post -1.43 EPS for the current fiscal year.Wall Street Analysts Forecast Growth
Separately, Piper Sandler began coverage on shares of Cue Biopharma in a research report on Sunday, November 20th. They set an "overweight" rating and a $7.00 price objective for the company.
Cue Biopharma Company Profile
(Get Rating)
Cue Biopharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease.
See Also
- Get a free copy of the StockNews.com research report on Cue Biopharma (CUE)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
CUE Biophma,Inc.(纳斯达克:CUE-GET评级)是空头股数12月份大幅下跌的目标。截至12月30日,空头股数共有592,200股,与12月15日的717,000股相比,下降了17.4%。以日均成交量13.37万股计算,目前短息比率为4.4天。
机构资金流入和流出
对冲基金最近增持或减持了该股。Annandale Capital LLC在第三季度购买了Cue Biophma价值约14.5万美元的新股。西格玛规划公司在第三季度将其在Cue Biophma的股票头寸增加了12.8%。西格玛规划公司目前拥有188,424股该公司股票,价值420,000美元,在此期间又购买了21,318股。康纳·克拉克和伦恩投资管理有限公司在第三季度购买了Cue Biophma价值约73,000美元的新股。Voss Capital LLC在第三季度将其在Cue Biophma的股票头寸增加了100.0%。沃斯资本有限责任公司在此期间又购买了10万股,现在拥有20万股该公司股票,价值44.6万美元。最后,P.A.W.Capital Corp在第三季度将其在Cue Biophma的股票头寸增加了14.3%。P.A.W.Capital Corp现在持有该公司20万股股票,价值44.6万美元,在此期间又购买了2.5万股。31.87%的股票由对冲基金和其他机构投资者持有。
到达提示生物咽喉警报:提示Biophma价格表现
纳斯达克:CUE在周五午盘交易中上涨0.11美元,触及3.49美元。该股有48,612股易手,而其平均成交量为94,893股。该业务的50日移动均线价格为3.16美元,200日移动均线价格为2.98美元。CUE Biophma的12个月低点为2.18美元,12个月高位为11.23美元。该公司的债务权益比为0.18,流动比率为6.04,速动比率为6.04。
CUE Biophma(纳斯达克:CUE-GET评级)上一次发布季度收益数据是在11月14日(星期一)。该公司公布了本季度每股收益(0.31美元),比普遍预期的(0.38美元)高出0.07美元。该公司本季度营收为70万美元,高于分析师预期的65万美元。CUE Biophma的净利润率为负500.66%,净资产回报率为负77.78%。研究分析师预测,Cue Biophma本财年的每股收益将达到1.43美元。华尔街分析师预测经济增长
另外,派珀·桑德勒在11月20日周日的一份研究报告中开始报道Cue Biophma的股票。他们为该公司设定了“增持”评级和7.00美元的目标价。
CUE Biophma公司简介
(获取评级)
CUE Biophma,Inc.是一家临床阶段的生物制药公司,致力于开发一种新型的专有生物药物,用于选择性调节人类免疫系统,以治疗广泛的癌症和自身免疫性疾病。它正在筹备中的领域包括免疫肿瘤学、CUE-100框架、CUE-200框架和自身免疫性疾病。
另请参阅
- 免费获取StockNews.com关于CUE Biophma的研究报告(CUE)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受《Cue Biophma Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cue Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧